Thyroid Cancer
EA3231
A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em
Physician and Research Staff Educational Material
This material is intended for promotional use among health care professionals and is NOT intended for use as patient educational material.
Physician Fact Sheet
